Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMYD3 | Q9H7B4 | 2/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.33 |
| ▸ | KDM1A | O60341 | 1/20 | 0.33 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | BLM | P54132 | 1/20 | 0.32 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.32 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.32 |
| ▸ | CASP6 | P55212 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14652102 | 0.85 | SMYD3 (0.40) | SMYD3L3MBTL1EPHX1KMT2AKDM1A | |
| SCHEMBL15906225 | 0.78 | EPHX1 (0.47) | SMYD3L3MBTL1EPHX1KMT2AKDM4E | |
| SCHEMBL2454699 | 0.78 | SMYD3 (0.40) | SMYD3L3MBTL1EPHX1KMT2AEPHX2 | |
| SCHEMBL2452220 | 0.77 | HPGD (0.40) | SMYD3L3MBTL1EPHX1KMT2AEPHX2 | |
| Hydrochloric Acid SCHEMBL3952772 | 0.76 | SMYD3 (0.45) | SMYD3L3MBTL1EPHX1KMT2AEPHX2 | |
| SCHEMBL14654933 | 0.74 | L3MBTL1 (0.37) | SMYD3L3MBTL1EPHX1EPHX2 | |
| SCHEMBL18431346 | 0.73 | L3MBTL1 (0.39) | SMYD3L3MBTL1EPHX1EPHX2 | |
| SCHEMBL18431408 | 0.73 | TEAD1 (0.40) | SMYD3L3MBTL1EPHX1EPHX2 | |
| SCHEMBL22388662 | 0.73 | TEAD1 (0.40) | SMYD3L3MBTL1EPHX1EPHX2 | |
| SCHEMBL2456036 | 0.72 | SMYD3 (0.44) | SMYD3KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130023514-A1 | SUBSTITUTED PYRROLOTRIAZINES AS PROTEIN KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130023514-A1 | SUBSTITUTED PYRROLOTRIAZINES AS PROTEIN KINASE INHIBITORS | STK25, MAP3K15, MAP3K5 | SMYD3 3232/4885L3MBTL1 4518/4885EPHX1 4242/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.